PhysioMimix® DILI assay kit: Human 24 for accurate DILI predictions and mechanistic hepatotoxicity insights

Drug-induced liver injury (DILI) is one of the leading causes of drug development failures, often emerging late in the drug development pipeline, when clinical trials are already underway. Traditional preclinical models struggle to predict complex, latent, and immune-related DILI mechanisms accurately, putting patients and investments at risk.

Gain deeper insights earlier in the process by utilizing the PhysioMimix DILI Assay Kit: Human 24. Leveraging our validated Liver-on-a-chip, it allows you to recreate our FDA-recognized DILI assay in your lab. This all-in-one kit enables you to effortlessly adopt Organ-on-a-chip technology and recreate human-relevant liver models with ease, providing a robust platform for evaluating complex and latent drug hepatotoxicity with greater accuracy.

Discover how the PhysioMimix DILI assay kit: Human 24:

• Accurately predicts human-relevant DILI mechanisms, including immune-mediated toxicity
• Reduces reliance on traditional in vitro and in vivo animal models that often fail to translate
• Improve confidence in drug safety before progressing to clinical trials
• Seamlessly integrate into your existing workflows for fast, reproducible results

To learn more, visit our PhysioMimix DILI assay kit: Human product page

Note. As of October 2025, PhysioMimix® OOC Systems mentioned in the video have been replaced by our universal PhysioMimix Core microphysiological system.